Targanta’s Oritavacin Faces Statistical Hurdle At Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is asking the Anti-Infective Drugs Advisory Committee to review the choice confidence interval in Targanta’s studies for the antibiotic oritavancin.
You may also be interested in...
Theravance’s Telavancin Prompts Renal Concerns, But No Questions From FDA
Safety signal from trials appears in FDA’s briefing materials, but not in list of questions for the Anti-Infective Drugs Advisory Committee.
Telavancin May Require Informed Consent For Women Of Childbearing Age
The Anti-Infective Drugs Advisory Committee will consider whether a REMS is necessary given the teratogenic risks of Theravance’s antibiotic.
Theravance’s Telavancin Prompts Renal Concerns, But No Questions From FDA
Safety signal from trials appears in FDA’s briefing materials, but not in list of questions for the Anti-Infective Drugs Advisory Committee.